Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

In 1993, Bowers and the FAA entered into a lease for office and warehouse space. The FAA agreed to monthly payments, $19,509, beginning in January 1994, payable each month “in arrears.” The parties modified the lease eight times until termination on September 30, 2006. In 2008, Bowers filed a claim of $82,203.72 with the contracting officer (41 U.S.C. 7103(a)(1)), for the final month’s rent and property damage. Bowers claimed that because the contract provided for payment “in arrears,” payment made in September, 2006 was for the August rent. The contracting officer held that rent was actually paid in advance, but allowed other, minor, claims. Before the Civilian Board of Contract Appeals, Bowers attempted to establish that the FAA had not paid rent for three months in 1994. CBCA rejected the attempt and Bowers signed a certificate of finality. In 2009 Bowers submitted two more claims: $56,640.78 (plus interest) for assertedly unpaid rent for January, February, and March of 1994 and that the FAA underpaid by $664 every month from October 1, 1998 to October 1, 2006, a total of $64,408.00 (plus interest). The contracting officer denied the claims. The Claims Court held that the CBCA’s final decision precluded the litigation. The Federal Circuit affirmed. View "Bowers Inv. Co, LLC v. United States" on Justia Law

In 1996, CP sued the United States, claiming that CP owned minerals underlying Louisiana property (Groups A, B, and C mineral servitudes), and that between 1943 and 1978, the government imposed a drilling and operations moratorium while the surface was used for bombing and artillery practice. It alleged that starting in 1992, the government, claiming ownership, has granted oil and gas leases covering the property. The district court granted the government summary judgment with regard to Groups A and B because the prescription period was not suspended by the moratoriums. Concerning Group C, the court granted CP summary judgment, finding that servitude imprescriptible. The Fifth Circuit affirmed; certiorari was denied. In1998, CP filed another complaint in the Claims Court, alleging taking without just compensation, as an alternative to its district court action. In 2004, the Claims Court dismissed the Groups A and B claims and limited the C claim to post-1992 action. The court found that the government’s issuance of leases after 1997 constituted a compensable temporary taking, but subsequently dismissed, finding that the facts alleged in the district court complaint were nearly identical. The complaints were “for or in respect to” the same claim and 28 U.S.C. 1500 precluded jurisdiction. The Federal Circuit affirmed. View "Cent. Pines Land Co., LLC v. United States" on Justia Law

A jury found that Demant and Widex infringed the 749 and 850 patents. The court entered judgment finding noninfringement of the 749 patent, finding that prosecution history estoppel barred the finding of infringement under the doctrine of equivalents. The patents relate to technology for reducing acoustic feedback in a programmable digital hearing aid. All hearing aids have: a microphone that picks up sound and converts it to an electrical signal, a speaker (receiver) that converts the signal back into sound waves, and sound processing circuitry that adjusts received sound to compensate for any hearing impairment. Some of the amplified sound from the speaker may also travel back to the microphone via an “acoustic feedback path” and is amplified along with all other sound arriving at the input microphone. The resulting cycle of amplification causes the whistling sound known as “feedback.” The common specification. with a 1986 priority date, describes a method of reducing feedback by creating an electrical feedback path and inserting a programmable filter in that path to mimic the effects of acoustic feedback on the phase and amplitude of a sound signal in the transmission channel. This electrical feedback signal then cancels the acoustic feedback signal. The Federal Circuit affirmed. View "Energy Transp. Group, Inc. v. Wm. Demant Holding A/S WDH, Inc." on Justia Law

Apple alleged that Samsung’s Galaxy Nexus smart-phone infringed patents, including the 604 patent. Asserted claim 6 of the 604 patent is directed to a “unified search” that uses heuristic modules to search multiple data storage locations. Unified search refers to ability to access information on more than one data storage location through a single interface and allows the user to search the device’s local memory and the Internet by entering a single search query. Apple alleged that the Quick Search Box unified search application of Galaxy Nexus infringes claim 6. QSB is a feature of Android, an open-source mobile software platform developed by Google. Any software developer may use Android to create applications and any handset manufacturer can install Android on a device. Galaxy Nexus is one of more than 300 available Android smartphones. The release of the allegedly infringing version of the Android platform predated release of Galaxy Nexus, but Google is not a defendant. The district court enjoined sale of the Galaxy Nexus based on the alleged infringement of the 604 patent. The Federal Circuit reversed. The record did not permit the inference that the allegedly infringing features of the Galaxy Nexus drive consumer demand or the court’s clam construction. View "Apple Inc. v. Samsung Elec. Co., Ltd." on Justia Law

SanDisk sued Kingston for infringement of four patents relating to aspects of flash memory for USB “thumbdrives,” computers, smart phones, and mp3 players. Flash memory continues to store data after a power source is removed. The district court granted Kingston summary judgment of non-infringement with respect to certain asserted claims. SanDisk dismissed its remaining infringement claims and appealed. The Federal Circuit affirmed in part, vacated in part, and remanded, first holding that it lacked jurisdiction to address certain claim construction arguments. With respect to other claims, the district court erred in its constructions of the “recording a relative time of programming ” limitation in certain claims and the “at least a user data portion and an overhead portion” limitation others. The court affirmed the judgment of no literal infringement of one claim, but vacated the judgment that Kingston did not infringe other claims under the doctrine of equivalents. View "Sandisk Corp. v. Kingston Tech. Co., Inc." on Justia Law

The 1989 Ethics Reform Act, 103 Stat. 1716, limited a federal judge’s ability to earn outside income, but provided for automatic, non-discretionary cost of living adjustments (COLA); whenever a COLA for General Schedule federal employees takes effect under 5 U.S.C. 5303, the salary of judges “shall be adjusted.” The only limitation on General Schedule COLAs is a presidential declaration of a “national emergency or serious economic conditions” 5 U.S.C. 5303(b). Nonetheless, in 1995, 1996, 1997, and 1999, General Schedule employees received adjustments, but Congress blocked adjustments for judges. Judges alleged violation of Article III, which provides that “Compensation” for federal judges “shall not be diminished during their Continuance in Office.” The district court agreed, but the Federal Circuit reversed, based on United States v. Will, 449 U.S. 200 (1980). In 2001, Congress enacted legislation blocking COLAs in certain years. Judges sought back pay. The Court of Federal Claims dismissed; the Federal Circuit affirmed. The Supreme Court vacated. On remand, the Federal Circuit held that the claim was not precluded, but affirmed dismissal. On rehearing en banc, the Federal Circuit overruled its earlier decision, holding that the 1989 Act triggered the Compensation Clause’s basic protections. In this unique context, the Constitution prevents Congress from abrogating that precise commitment to COLAs. The 1989 Act controls over the 2001 enactments. View "Beer v. United States" on Justia Law

MT filed an application with the Patent and Trademark Office, to register the mark JPK PARIS 75 in connection with sunglasses, wallets, handbags and purses, travel bags, suitcases, belts, and shoes. “JPK” are the initials of Klifa, the manager of MT and designer of the goods at issue. MT submitted four articles discussing consumer purchasing decisions and a declaration from Klifa, a French citizen who lived in Paris for 22 years until 1986, currently residing in the U.S., indicating that he exhibited at trade shows in Paris. The examining attorney refused to register the mark, finding it “primarily geographically deceptively misdescriptive” in relation to the goods, Lanham Act, 15 U.S.C. 1052(e)(3). The Board affirmed, rejecting an argument that the monogram “JPK” is the dominant portion of the mark, and finding that using “Paris” in the mark “serves to identify the geographic origin of the products” such that consumers would assume that the products have a connection with Paris either in their manufacture or design. The Board found the evidence sufficient to show that a substantial portion of relevant consumers would be deceived into believing that the goods came from Paris. The Federal Circuit affirmed. View "In re Miracle Tuesday, LLC" on Justia Law

Belkin filed a request for inter partes reexamination of the 281 patent, which is directed to a wireless router, alleging 10 substantial new questions of patentability regarding claims 1–32 based on four prior art references. The Director determined that the first three references did not raise a substantial new question of patentability, but that the issue of anticipation by the Peirce patent did raise such a question as to claims 1–3 and 8–10 and ordered reexamination of those claims. The examiner then issued an Action Closing Prosecution addressing only proposed rejection of claims 1–3 and 8–10 as anticipated by Peirce. A Right of Appeal Notice issued, addressing only anticipation by Peirce. Belkin appealed to the Board, challenging the examiner’s failure to make rejections involving the other three references. The Board determined that it did not have jurisdiction under 35 U.S.C. 312(c) and that there had been no final decision on patentability regarding the three references under 35 U.S.C. 315(b). The Board affirmed with regard to the Peirce reference. The Federal Circuit affirmed. The Board did not err in refusing to consider issues that the Director found not to raise a substantial new question of patentability. View "Belkin Int'l, Inc. v. Kappos" on Justia Law

Abbott owns the 752 patent and the 509 patent, which share a common specification that describes methods and devices “for the in vivo monitoring of an analyte using an electrochemical sensor to provide information to a patient about the level of the analyte” in the bloodstream. The specification describes methods and devices for monitoring glucose levels for diabetics. And notes that a variety of devices exist for monitoring glucose levels in the blood stream, but some of these devices include sensor guides that are “typically bulky and do not allow for freedom of movement.” In response to a third-party request for reexamination, the Board of Patent Appeals and Interferences rejected several claims in the patents as indefinite, anticipated, or obvious over several combinations of prior art references. The Federal Circuit vacated in part, noting that the U.S. PTO conceded that the examiner’s official notice rejections should be withdrawn. The rejections were based on unreasonable claim constructions; under the broadest reasonable construction, “electrochemical sensor” is properly interpreted to mean a discrete electrochemical sensor devoid of external connection cables or wires to connect to a sensor control unit. View "In re Abbott Diabetes Care, Inc." on Justia Law

Pozen developed a method for treating migraines by combining two drugs, sumatriptan and naproxen, in a single tablet, which it markets with GlaxoSmithKline as Treximet. Sumatriptan, a 5-HT receptor agonist, was developed in the late 1980s and is widely accepted as an effective medicine for migraines, but it does not prevent the reoccurrence of migraine symptoms. Naproxen is anonsteriodal anti-inflammatory drug. Pozen filed a New Drug Application (NDA) for Treximet and obtained approval from the FDA in 2008; the relevant patents are included in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), 21 U.S.C. 355(b)(1). Generic pharmaceutical manufacturers filed ANDAs (abbreviated new drug applications) to market generic forms of Treximet before the expiration of Pozen’s patents, certifying that the patents listed in the Orange Book are “invalid or will not be infringed” by the generic products. Thereafter, Pozen filed complaints for infringement, 35 U.S.C. 271(e)(2)(A). The district court held that Pozen’s patents are not invalid as obvious under 35 U.S.C. 103 and were infringed by the ANDA filings and enjoined the generic manufacturers from making, using, importing, selling or offering to sell their generic products in the United States. The Federal Circuit affirmed. View "Pozen, Inc. v. Par Pharma., Inc." on Justia Law